Log in
Enquire now
‌

US Patent 11008572 Methods and compositions for modulating splicing

Patent 11008572 was granted and assigned to Skyhawk Therapeutics on May, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
Skyhawk Therapeutics
Skyhawk Therapeutics
Date Filed
February 4, 2020
Date of Patent
May 18, 2021
Patent Applicant
Skyhawk Therapeutics
Skyhawk Therapeutics
Patent Application Number
16781803
Patent Citations
‌
US Patent 10195196 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
‌
US Patent 10196639 Modulation of gene expression and screening for deregulated protein expression
‌
US Patent 10252984 Inhibiting G protein coupled receptor 6 kinase polypeptides
‌
US Patent 10377742 AMPK-activating heterocyclic compounds and methods for using the same
‌
US Patent 10358427 Modulators of indoleamine 2,3-dioxygenase
‌
US Patent 10006027 Methods for modulating Ataxin 2 expression
‌
US Patent 10053697 Programmable alternative splicing devices and uses thereof
‌
US Patent 10076519 Substituted pyridazines as skeletal muscle modulators
‌
US Patent 10093678 Azaspiro derivatives as TRPM8 antagonists
‌
US Patent 10112923 1,2,4-triazine-4-amine derivatives
Patent Citations Received
‌
US Patent 11326165 Methods and compositions for modulating splicing
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11008572
Patent Primary Examiner
‌
Kristin A Vajda

Find more entities like US Patent 11008572 Methods and compositions for modulating splicing

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.